Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 1,605 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a sale of 1,605 shares of common stock on December 22, 2025.
- The shares were sold at a price of $34.556 per share.
- This transaction was a 'sell to cover' to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units and was not a discretionary trade.
- Following this transaction, Ms. Leproust beneficially owns 874,313 shares of common stock directly.
- The filing also details various employee stock options held by Ms. Leproust, including 64,950 performance stock options that vested on December 19, 2022, upon meeting applicable performance criteria.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is neutral in sentiment. The vesting of performance options is a positive indicator of management achievement.
Positives
- Vesting of 64,950 performance stock options on December 19, 2022, indicates that the reporting person met applicable performance criteria.
Negatives
- The sale of 1,605 shares, even for tax purposes, reduces the direct beneficial ownership of common stock.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's view of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 2016-09-01 | 25% of shares subject to an employee stock option (exercise price $5.95) vested. |
| 2017-09-28 | 10% of shares subject to an employee stock option (exercise price $8.82) vested. |
| 2018-09-28 | 15% of shares subject to an employee stock option (exercise price $8.82) vested. |
| 2019-10-31 | 20% of shares subject to an employee stock option (exercise price $26.66) vested and became exercisable. |
| 2020-09-01 | Performance stock options (exercise price $67.85) granted to the reporting person. |
| 2020-10-24 | 25% of shares subject to an employee stock option (exercise price $23.33) vested. |
| 2022-12-19 | 64,950 performance stock options vested and became exercisable as a result of meeting applicable performance criteria. |
| 2025-09-28 | Expiration date for an employee stock option (exercise price $8.82). |
| 2025-10-23 | Expiration date for an employee stock option (exercise price $23.33). |
| 2025-12-22 | Transaction date for the sale of 1,605 shares of common stock by Emily M. Leproust. |
| 2025-12-23 | Signature date of the reporting person's attorney-in-fact for the filing. |
| 2027-09-28 | Expiration date for an employee stock option (exercise price $8.82). |
| 2028-11-18 | Expiration date for an employee stock option (exercise price $26.66). |
| 2029-10-23 | Expiration date for an employee stock option (exercise price $23.33). |
| 2030-08-31 | Expiration date for an employee stock option (exercise price $67.85). |
Keywords
Twist Bioscience, TWST, Emily M. Leproust, Insider Trading, Form 4, Stock Sale, CEO, Restricted Stock Units, Performance Options, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.